4D Molecular Therapeutics recently released positive interim results from the extension cohort of the phase 2 PRISM study. Find out more on FDMT stock here.

Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial ...

4D Molecular Therapeutics accelerates Phase 3 trial timelines and streamlines operations to focus on wet AMD treatments.

All three 4DMT clinical-stage ophthalmic product candidates utilize the R100 vector, including 4D-150 for wet age-related macular degeneration and diabetic macular edema.

Astellas Pharma is digging up some cash to use one of 4D Molecular Therapeutics’ gene therapy vectors for at least one rare eye disease—but the genetic medicines company is going to have to wa ...

SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...

Astellas Pharma and 4D Molecular Therapeutics have entered into a license agreement that grants Astellas the rights to utilize 4DMT’s intravitreal retinotopic R100 vector for treating rare ...

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets ...